M.D. Anderson Unveils Mammography Van

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

HOUSTON--Just in time for Breast Cancer Awareness Month, The University of Texas M.D. Anderson Cancer Center has unveiled a mobile mam-mography program that will bring screening mammography to corporate and community locations throughout the Houston area.

HOUSTON--Just in time for Breast Cancer Awareness Month, The Universityof Texas M.D. Anderson Cancer Center has unveiled a mobile mam-mographyprogram that will bring screening mammography to corporate andcommunity locations throughout the Houston area.

The LifeCheq Mobile Mammography Van, funded by a gift from theHouston Chapter of The Susan G. Komen Breast Cancer Foundation,made its debut at the Race for the Cure October 5. This event,sponsored by the Komen Foundation, benefits breast health careand education and breast cancer research.

The van, staffed by M.D. Anderson personnel, can be reserved byTexas companies and community organizations that wish to provideon-site screening mammography for their female employees or members.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content